BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trevisan França de Lima L, Broszczak D, Zhang X, Bridle K, Crawford D, Punyadeera C. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 2020;1874:188451. [PMID: 33065194 DOI: 10.1016/j.bbcan.2020.188451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Moldogazieva NT, Zavadskiy SP, Terentiev AA. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine. Cancer Genomics Proteomics 2021;18:369-83. [PMID: 33994362 DOI: 10.21873/cgp.20266] [Reference Citation Analysis]
2 Han Z, Li K, Wu J, Wang K, Qiu C, Ye H, Cui C, Song C, Wang K, Shi J, Wang P, Zhang J. Diagnostic value of RNA for hepatocellular carcinoma: a network meta-analysis. Biomark Med 2021;15:1755-67. [PMID: 34783583 DOI: 10.2217/bmm-2021-0327] [Reference Citation Analysis]
3 Lin Z, Xu Q, Miao D, Yu F. An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma. Front Oncol 2021;11:644416. [PMID: 33828988 DOI: 10.3389/fonc.2021.644416] [Reference Citation Analysis]
4 Takahashi K, Ofuji K, Hiramatsu K, Nosaka T, Naito T, Matsuda H, Endo K, Higuchi M, Ohtani M, Nemoto T, Nakamoto Y. Circulating tumor cells detected with a microcavity array predict clinical outcome in hepatocellular carcinoma. Cancer Med 2021;10:2300-9. [PMID: 33675149 DOI: 10.1002/cam4.3790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Li J, Yan S. MiR-466 Inhibits the Progression of Severe Hepatocellular Carcinoma via Regulating FMNL2-Mediated Activation of NF-κB and Wnt/β-Catenin Pathways. J Oncol 2021;2021:3554219. [PMID: 34257650 DOI: 10.1155/2021/3554219] [Reference Citation Analysis]
6 Pan Q, Qin F, Yuan H, He B, Yang N, Zhang Y, Ren H, Zeng Y. Normal tissue adjacent to tumor expression profile analysis developed and validated a prognostic model based on Hippo-related genes in hepatocellular carcinoma. Cancer Med 2021;10:3139-52. [PMID: 33818013 DOI: 10.1002/cam4.3890] [Reference Citation Analysis]
7 Habash NW, Sehrawat TS, Shah VH, Cao S. Epigenetics of Alcohol-Related Liver Diseases. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol 2021;74:1212-24. [PMID: 33545267 DOI: 10.1016/j.jhep.2021.01.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Chen J, Yang J, Xu Q, Wang Z, Wu J, Pan L, Huang K, Wang C. Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep 2021;41:BSR20202063. [PMID: 33605411 DOI: 10.1042/BSR20202063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Neuberger J, Cain O. The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics. Hepat Med 2021;13:59-69. [PMID: 34163263 DOI: 10.2147/HMER.S278076] [Reference Citation Analysis]
11 Zeng C, Ye S, Chen Y, Zhang Q, Luo Y, Gai L, Luo B. HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis. J Immunol Res 2021;2021:9289719. [PMID: 34988230 DOI: 10.1155/2021/9289719] [Reference Citation Analysis]
12 Xu Y, Yu X, Sun Z, He Y, Guo W. Roles of lncRNAs Mediating Wnt/β-Catenin Signaling in HCC. Front Oncol 2022;12:831366. [PMID: 35356220 DOI: 10.3389/fonc.2022.831366] [Reference Citation Analysis]
13 Wang LP, Lin J, Ma XQ, Xu DY, Shi CF, Wang W, Jiang XJ. Exosomal DLX6-AS1 from hepatocellular carcinoma cells induces M2 macrophage polarization to promote migration and invasion in hepatocellular carcinoma through microRNA-15a-5p/CXCL17 axis. J Exp Clin Cancer Res 2021;40:177. [PMID: 34039401 DOI: 10.1186/s13046-021-01973-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 He F, Chen G, He R, Huang Z, Li J, Wu W, Chen J, Tang Y, Li D, Pan S, Feng Z, Dang Y. Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways. PeerJ 2022;10:e12944. [DOI: 10.7717/peerj.12944] [Reference Citation Analysis]
15 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Maravelia P, Silva DN, Rovesti G, Chrobok M, Stål P, Lu YC, Pasetto A. Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. Cancers (Basel) 2021;13:4334. [PMID: 34503144 DOI: 10.3390/cancers13174334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]